CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ:CRIS), a drug development company focusing on signaling pathway drug technologies to create new medicines primarily for cancer, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2006.
